Cited by 223Schizophrenia research and treatmentCardiac Health and Mental HealthLipoproteins and Cardiovascular Health

The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.

Antipsychotic effects on estimated 10-year coronary heart disease risk in the CATIE schizophrenia study

Open access

Daumit, Gail L., Goff, Donald C., Meyer, Jonathan M., Davis, Vicki G., Nasrallah, Henry A., McEvoy, Joseph P., Rosenheck, Robert, Davis, Sonia M., Hsiao, John K., Stroup, T. Scott, Lieberman, Jeffrey A.·2008·Schizophrenia Research

DOI 10.1016/j.schres.2008.07.006PMC PMC2614656

Open this paper in CoChat — free account

Abstract

Objective Persons with schizophrenia die earlier than the general population, in large part due to cardiovascular disease. The study objective was to examine effects of different antipsychotic treatments on estimates of 10-year coronary heart disease (CHD) risk calculated by the Framingham Heart Study formula.Method Change in 10-year risk for CHD was compared between treatment groups in 1125 patients followed for 18 months or until treatment discontinuation in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Schizophrenia Trial.Results The covariate-adjusted mean change in 10-year CHD risk differed significantly between treatments. Olanzapine was associated with a 0.5% (SE 0.3) increase and quetiapine, a 0.3% (SE 0.3) increase; whereas risk decreased in patients treated with perphenazine, -0.5% (SE 0.3), risperidone, -0.6% (SE 0.3), and ziprasidone -0.6% (SE 0.4). The difference in 10-year CHD risk between olanzapine and risperidone was statistically significant (p=0.004). Differences in estimated 10-year CHD risk between drugs were most marked in the tertile of subjects with a baseline CHD risk of at least 10%. Among individual CHD risk factors used in the Framingham formula, only total and HDL cholesterol levels differed between treatments.Conclusions These results indicate that the impact on 10-year CHD risk differs significantly between antipsychotic agents, with olanzapine producing the largest elevation in CHD risk of the agents studied in CATIE.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/j.schres.2008.07.006

Cites

44 of 44 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure<SUBTITLE>The JNC 7 Report</SUBTITLE>
Chobanian, A. V. (2003) · JAMA · doi:10.1001/jama.289.19.2560 · Cited by 25,386
Prediction of coronary heart disease using risk factor categories
Wilson, P. W. F., D’Agostino, R. B., Levy, D., Belanger, A. M., Silbershatz, H., & Kannel, W. B. (1998) · Circulation · doi:10.1161/01.cir.97.18.1837 · Cited by 9,581
Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia
Lieberman, J. A., Stroup, T. S., McEvoy, J. P., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., Keefe, R. S. E., Davis, S. M., Davis, C. E., Lebowitz, B. D., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051688 · Cited by 5,892
Self-citation
Antipsychotic-induced weight gain: a comprehensive research synthesis
Allison, D. B., Mentore, J. L., Heo, M., Chandler, L. P., Cappelleri, J. C., Infante, M. C., & Weiden, P. J. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.11.1686 · Cited by 2,382
Validation of the Framingham Coronary Heart Disease Prediction Scores: Results of a Multiple Ethnic Groups Investigation
D'Agostino, R. B., Grundy, S., Sullivan, L. M., Wilson, P., & for the CHD Risk Prediction Group (2001) · JAMA · doi:10.1001/jama.286.2.180 · Cited by 2,108
Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women
Nordestgaard, B. G., Benn, M., Schnohr, P., & Tybjærg-Hansen, A. (2007) · JAMA · doi:10.1001/jama.298.3.299 · Cited by 2,058
The Fifth Report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC V)
(1993) · Archives of Internal Medicine · doi:10.1001/archinte.1993.00410020010002 · Cited by 1,974
Consensus development conference on antipsychotic drugs and obesity and diabetes
American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, & North American Association for the Study of Obesity (2004) · Diabetes Care · doi:10.2337/diacare.27.2.596 · Cited by 1,554
Congruencies in increased mortality rates, years of potential life lost, and causes of death among public mental health clients in eight states.
(2006) · Europe PMC (PubMed Central) · Cited by 1,299
Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III.
Mcevoy, J., Meyer, J., Goff, D., Nasrallah, H., Davis, S., Sullivan, L., Meltzer, H., Hsiao, J. K., Stroup, T., & Lieberman, J. (2005) · Schizophrenia Research · doi:10.1016/j.schres.2005.07.014 · Cited by 1,220
Self-citation

Show all 44 references

Sorted by citations

Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care
DE HERT, M., CORRELL, C. U., BOBES, J., CETKOVICH‐BAKMAS, M., COHEN, D., ASAI, I., DETRAUX, J., GAUTAM, S., MÖLLER, H., NDETEI, D. M., et al. (2011) · World Psychiatry · doi:10.1002/j.2051-5545.2011.tb00014.x · Cited by 2,488
11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study)
Tiihonen, J., Lönnqvist, J., Wahlbeck, K., Klaukka, T., Niskanen, L., Tanskanen, A., & Haukka, J. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60742-x · Cited by 1,354
Cardiometabolic Risk of Second-Generation Antipsychotic Medications During First-Time Use in Children and Adolescents
Correll, C. U. (2009) · JAMA · doi:10.1001/jama.2009.1549 · Cited by 1,050
Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC)
De Hert, M., Dekker, J. M., Wood, D., Kahl, K. G., Holt, R. I. G., & Möller, H.-J. (2009) · European Psychiatry · doi:10.1016/j.eurpsy.2009.01.005 · Cited by 951
Excess early mortality in schizophrenia.
Laursen, T. M., Nordentoft, M., & Mortensen, P. B. (2014) · Annual Review of Clinical Psychology · doi:10.1146/annurev-clinpsy-032813-153657 · Cited by 913
Excess mortality, causes of death and life expectancy in 270,770 patients with recent onset of mental disorders in Denmark, Finland and Sweden
Nordentoft, M., Wahlbeck, K., Hällgren, J., Westman, J., Ösby, U., Alinaghizadeh, H., Gissler, M., & Laursen, T. M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0055176 · Cited by 778
Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: A systematic review and meta-analysis
Rummel‐Kluge, C., Komossa, K., Schwarz, S., Hunger, H., Schmid, F., Lobos, C. A., Kissling, W., Davis, J. M., & Leucht, S. (2010) · Schizophrenia Research · doi:10.1016/j.schres.2010.07.012 · Cited by 698
Quetiapine versus other atypical antipsychotics for schizophrenia
Komossa, K., Rummel‐Kluge, C., Schmid, F., Hunger, H., Schwarz, S., Srisurapanont, M., Kissling, W., & Leucht, S. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006625.pub2 · Cited by 261
Ziprasidone versus other atypical antipsychotics for schizophrenia
Komossa, K., Rummel‐Kluge, C., Hunger, H., Schwarz, S., Bhoopathi, P. S., Kissling, W., & Leucht, S. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006627.pub2 · Cited by 243
Interaction Between Atypical Antipsychotics and the Gut Microbiome in a Bipolar Disease Cohort
Flowers, S. A., Evans, S. J., Ward, K. M., McInnis, M. G., & Ellingrod, V. L. (2017) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1890 · Cited by 235
Influence of antipsychotics on mortality in schizophrenia: systematic review
Weinmann, S., Read, J., & Aderhold, V. (2009) · Schizophrenia Research · doi:10.1016/j.schres.2009.05.018 · Cited by 224
Antipsychotic-Induced Insulin Resistance and Postprandial Hormonal Dysregulation Independent of Weight Gain or Psychiatric Disease
Teff, K. L., Rickels, M. R., Grudziak, J., Fuller, C., Nguyen, H.-L., & Rickels, K. (2013) · Diabetes · doi:10.2337/db13-0430 · Cited by 195
Review of the evidence: prevalence of medical conditions in the United States population with serious mental illness
Janssen, E. M., McGinty, E. E., Azrin, S. T., Juliano‐Bult, D., & Daumit, G. L. (2015) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2015.03.004 · Cited by 201
Self-citation
An evaluation of the safety and efficacy of cariprazine in patients with acute exacerbation of schizophrenia: A phase II, randomized clinical trial
Durgam, S., Starace, A., Li, D., Migliore, R., Ruth, A., Németh, G., & Laszlovszky, I. (2014) · Schizophrenia Research · doi:10.1016/j.schres.2013.11.041 · Cited by 194
Metabolic syndrome with the atypical antipsychotics
Pramyothin, P., & Khaodhiar, L. (2010) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0b013e32833de61c · Cited by 174
The CHANGE trial: no superiority of lifestyle coaching plus care coordination plus treatment as usual compared to treatment as usual alone in reducing risk of cardiovascular disease in adults with schizophrenia spectrum disorders and abdominal obesity
Speyer, H., Christian Brix Nørgaard, H., Birk, M., Karlsen, M., Storch Jakobsen, A., Pedersen, K., Hjorthøj, C., Pisinger, C., Gluud, C., Mors, O., et al. (2016) · World Psychiatry · doi:10.1002/wps.20318 · Cited by 153
Metformin for Weight Loss and Metabolic Control in Overweight Outpatients With Schizophrenia and Schizoaffective Disorder
Jarskog, L. F., Hamer, R. M., Catellier, D. J., Stewart, D. D., LaVange, L., Ray, N., Golden, L. H., Lieberman, J. A., Stroup, T. S., & for the METS Investigators (2013) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2013.12010127 · Cited by 145
Self-citation
Diabetes and Cardiovascular Care Among People with Severe Mental Illness: A Literature Review
Mangurian, C. V., Newcomer, J. W., Modlin, C., & Schillinger, D. (2016) · Journal of General Internal Medicine · doi:10.1007/s11606-016-3712-4 · Cited by 124
Total anticholinergic burden and risk of mortality and cardiovascular disease over 10 years in 21,636 middle-aged and older men and women of EPIC-Norfolk prospective population study
Myint, P. K., Fox, C., Kwok, C. S., Luben, R., Wareham, N. J., & Khaw, K. (2014) · Age and Ageing · doi:10.1093/ageing/afu185 · Cited by 109
Metabolic issues in patients affected by schizophrenia: clinical characteristics and medical management
Ventriglio, A., Gentile, A., Stella, E., & Bellomo, A. (2015) · Frontiers in Neuroscience · doi:10.3389/fnins.2015.00297 · Cited by 115
Effects of atypical antipsychotic treatment and resistant starch supplementation on gut microbiome composition in a cohort of patients with bipolar disorder or schizophrenia
Flowers, S. A., Baxter, N. T., Ward, K. M., Kraal, A. Z., McInnis, M. G., Schmidt, T. M., & Ellingrod, V. L. (2019) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2214 · Cited by 100
Metabolic syndrome in bipolar disorder and schizophrenia: dietary and lifestyle factors compared to the general population
Bly, M. J., Taylor, S. F., Dalack, G. W., Pop‐Busui, R., Burghardt, K. J., Evans, S. J., McInnis, M. G., Grove, T. B., Brook, R. D., Zöllner, S. K., et al. (2013) · Bipolar Disorders · doi:10.1111/bdi.12160 · Cited by 106
Increased Food Intake and Energy Expenditure Following Administration of Olanzapine to Healthy Men
Fountaine, R. J., Taylor, A. E., Mancuso, J. P., Greenway, F. L., Byerley, L. O., Smith, S. R., Most, M. M., & Fryburg, D. A. (2010) · Obesity · doi:10.1038/oby.2010.6 · Cited by 102
Heart disease treatment and mortality in schizophrenia and bipolar disorder – Changes in the danish population between 1994 and 2006
Laursen, T. M., & Nordentoft, M. (2011) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2010.04.027 · Cited by 93
Review: Are there modifiable risk factors which will reduce the excess mortality in schizophrenia?
Wildgust, H. J., & Beary, M. (2010) · Journal of Psychopharmacology · doi:10.1177/1359786810384639 · Cited by 97
Cardiovascular aspects of antipsychotics
Raedler, T. J. (2010) · Current Opinion in Psychiatry · doi:10.1097/yco.0b013e32833f46c9 · Cited by 89
The association between weight change and symptom reduction in the CATIE schizophrenia trial
Hermes, E. D. A., Nasrallah, H. A., Davis, V. G., Meyer, J. M., McEvoy, J. P., GOFF, D. C., Thomas, S., Stroup, T. S., Swartz, M. S., Lieberman, J. A., et al. (2011) · Schizophrenia Research · doi:10.1016/j.schres.2011.01.022 · Cited by 87
Self-citation
Schizophrenia and Depression Co-Morbidity: What We have Learned from Animal Models
Samsom, J., & Wong, A. H. C. (2015) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2015.00013 · Cited by 88
Motivations and Limitations Associated with Vaping among People with Mental Illness: A Qualitative Analysis of Reddit Discussions
Sharma, R., Wigginton, B., Meurk, C., Ford, P. J., & GARTNER, C. E. (2016) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph14010007 · Cited by 79
Antipsychotics cardiotoxicity: What's known and what's next
Li, X., Tang, X.-R., & Li, L. (2021) · World Journal of Psychiatry · doi:10.5498/wjp.v11.i10.736 · Cited by 80
Antipsychotics and mortality in first-onset schizophrenia: Prospective Finnish register study with 5-year follow-up
Kiviniemi, M., Suvisaari, J., Koivumaa-Honkanen, H. T., Häkkinen, U., Isohanni, M. K., & Hakko, H. H. (2013) · Schizophrenia Research · doi:10.1016/j.schres.2013.07.043 · Cited by 78
Risk of weight gain for specific antipsychotic drugs: a meta-analysis
Spertus, J. V., Horvitz-Lennon, M. V., Abing, H. K., & Normand, S. T. (2018) · Schizophrenia · doi:10.1038/s41537-018-0053-9 · Cited by 81
Cardiovascular effects of psychotic illnesses and antipsychotic therapy
Howell, S., Yarovova, E., Khwanda, A., & Rosen, S. D. (2019) · Heart · doi:10.1136/heartjnl-2017-312107 · Cited by 74
The challenge of reducing smoking in people with serious mental illness
Sharma, R., GARTNER, C. E., & Hall, W. (2016) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(16)30228-4 · Cited by 71
Drug-induced obesity and its metabolic consequences: a review with a focus on mechanisms and possible therapeutic options
Verhaegen, A. A., & Gaal, L. F. V. (2017) · Journal of Endocrinological Investigation · doi:10.1007/s40618-017-0719-6 · Cited by 75
Quetiapine versus other atypical antipsychotics for schizophrenia
Asmal, L., Flegar, S. J., Wang, J., Rummel‐Kluge, C., Komossa, K., & Leucht, S. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006625.pub3 · Cited by 70
A Qualitative Study of Social Facilitators and Barriers to Health Behavior Change Among Persons with Serious Mental Illness
Aschbrenner, K. A., Carpenter-Song, E. A., Mueser, K. T., Kinney, A., Pratt, S. I., & Bartels, S. J. (2012) · Community Mental Health Journal · doi:10.1007/s10597-012-9552-8 · Cited by 64
Antipsychotics and Schizophrenia: From Efficacy and Effectiveness to Clinical Decision-Making
Foussias, G., & Remington, G. J. (2010) · The Canadian Journal of Psychiatry · doi:10.1177/070674371005500302 · Cited by 59
Changes in weight and metabolic parameters during treatment with antipsychotics and metformin: do the data inform as to potential guideline development? A systematic review of clinical studies
Bushe, C., Bradley, A. J., Doshi, S., & Karagianis, J. L. (2009) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2009.02224.x · Cited by 58
Increased Framingham 10-year risk of coronary heart disease in middle-aged and older patients with psychotic symptoms
Jin, H., Folsom, D. P., Sasaki, A., Mudaliar, S. R. D., Henry, R. R., Torres, M., Golshan, S., Glorioso, D., & Jeste, D. V. (2010) · Schizophrenia Research · doi:10.1016/j.schres.2010.10.029 · Cited by 55
Drugs affecting body weight, body fat distribution, and metabolic function—mechanisms and possible therapeutic or preventive measures: an update.
Verhaegen, A. A., & Van Gaal, L. F. (2021) · Current Obesity Reports · doi:10.1007/s13679-020-00419-5 · Cited by 53
Metabolic syndrome and associated cardiovascular risk factors in the treatment of persons with human immunodeficiency virus and severe mental illness
Vergara-Rodriguez, P., Vibhakar, S., & Watts, J. (2009) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2009.07.004 · Cited by 53
Olanzapine depot formulation in rat: a step forward in modelling antipsychotic-induced metabolic adverse effects
Skrede, S., Martins, L., Berge, R. K., Steen, V. M., López, M., & Fernø, J. (2013) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145713000862 · Cited by 56
Comparison of Longer-Term Safety and Effectiveness of 4 Atypical Antipsychotics in Patients Over Age 40
Jin, H., Shih, P.-A. B., Golshan, S., Mudaliar, S. R. D., Henry, R. R., Glorioso, D., Arndt, S. V., KRAEMER, H. C., & Jeste, D. V. (2012) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.12m08001 · Cited by 56
A review of the safety and tolerability of aripiprazole
Pae, C. (2009) · Expert Opinion on Drug Safety · doi:10.1517/14740330902835493 · Cited by 50
Switching Antipsychotic Medications to Reduce Adverse Event Burden in Schizophrenia: Establishing Evidence-Based Practice
Newcomer, J. W., Weiden, P. J., & Buchanan, R. W. (2013) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.12028ah1 · Cited by 51
The Impact of Lifestyle Factors on the Physical Health of People with a Mental Illness: a Brief Review
Stanley, S. H., & Laugharne, J. D. E. (2013) · International Journal of Behavioral Medicine · doi:10.1007/s12529-013-9298-x · Cited by 51
Clinical Guidelines for the Physical Care of Mental Health Consumers : A Comprehensive Assessment and Monitoring Package for Mental Health and Primary Care Clinicians
Stanley, S. H., & Laugharne, J. D. E. (2011) · Australian & New Zealand Journal of Psychiatry · doi:10.3109/00048674.2011.614591 · Cited by 51
Higher mortality and years of potential life lost of suicide in patients with schizophrenia
Ko, Y. S., Tsai, H.-C., Chi, M. H., Su, C., Lee, I. H., Chen, P. S., Chen, K. C., & Yang, Y. K. (2018) · Psychiatry Research · doi:10.1016/j.psychres.2018.09.038 · Cited by 54
The atypical antipsychotic quetiapine induces hyperlipidemia by activating intestinal PXR signaling
Meng, Z., Gwag, T., Sui, Y., Park, S., Zhou, X., & Zhou, C. (2019) · JCI Insight · doi:10.1172/jci.insight.125657 · Cited by 52
High mortality and low access to care following incident acute myocardial infarction in individuals with schizophrenia
Kurdyak, P. A., Vigod, S. N., Calzavara, A. J., & Wodchis, W. P. (2012) · Schizophrenia Research · doi:10.1016/j.schres.2012.09.003 · Cited by 49
Neural Correlates of Weight Gain With Olanzapine
Mathews, J., Newcomer, J. W., Mathews, J. R., Fales, C. L., Pierce, K. J., Akers, B., Marcu, I., & Barch, D. M. (2012) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2012.934 · Cited by 50
Use of 12-Month Renal Function and Baseline Clinical Factors to Predict Long-Term Graft Survival
Schnitzler, M. A., Lentine, K. L., Axelrod, D. A., Gheorghian, A., You, M., Kalsekar, A., & L'Italien, G. J. (2011) · Transplantation · doi:10.1097/tp.0b013e31823ec02a · Cited by 48
Cardiovascular risk assessment in patients with a severe mental illness: a systematic review and meta-analysis
Boreu, Q. F., Martin, M., Flores‐Mateo, G., Zabaleta‐del‐Olmo, E., Ayerbe, L., López, M. P.-P., Martín‐Lopez, L. M., Montes‐Hidalgo, J., & Violán, C. (2016) · BMC Psychiatry · doi:10.1186/s12888-016-0833-6 · Cited by 46
DIABETIC KETOACIDOSIS ASSOCIATED WITH ANTIPSYCHOTIC DRUGS: CASE REPORTS AND A REVIEW OF LITERATURE
Vuk, A., Kuzman, M. R., Baretić, M., & Osvatić, M. M. (2017) · Psychiatria Danubina · doi:10.24869/psyd.2017.121 · Cited by 48
Cost-effectiveness model comparing olanzapine and other oral atypical antipsychotics in the treatment of schizophrenia in the United States
Furiak, N. M., Ascher‐Svanum, H., Klein, R. W., Smolen, L. J., Lawson, A. H., Conley, R. R., & Culler, S. D. (2009) · Cost Effectiveness and Resource Allocation · doi:10.1186/1478-7547-7-4 · Cited by 45
Antipsychotic drug treatment for elderly people with late-onset schizophrenia
Essali, A., & Ali, G. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004162.pub2 · Cited by 45
Cardio-metabolic risk and its management in a cohort of clozapine-treated outpatients
Lappin, J., Wijaya, M., Watkins, A., Morell, R., Teasdale, S. B., Lederman, O., Rosenbaum, S., Dick, S., Ward, P. B., & Curtis, J. (2018) · Schizophrenia Research · doi:10.1016/j.schres.2018.02.035 · Cited by 45
The risk of physical multimorbidity in people with psychotic disorders: A systematic review and meta-analysis
Rodrigues, M., Wiener, J. C., Stranges, S., Ryan, B. L., & Anderson, K. K. (2020) · Journal of Psychosomatic Research · doi:10.1016/j.jpsychores.2020.110315 · Cited by 46
Psychological Co-morbidities of Physical Illness
Pagoto, S. (2011) · Springer eBooks · doi:10.1007/978-1-4419-0029-6 · Cited by 44
The unchanging mortality gap for people with schizophrenia.
Chwastiak, L. A., & Tek, C. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61072-2 · Cited by 41
Potential gains in life expectancy from reducing amenable mortality among people diagnosed with serious mental illness in the United Kingdom
Dregan, A., McNeill, A., Gaughran, F., Jones, P. B., Bazley, A., Cross, S., Lillywhite, K., Armstrong, D., Smith, S., Osborn, D. P. J., et al. (2020) · PLOS ONE · doi:10.1371/journal.pone.0230674 · Cited by 41
Olanzapine depot exposure in male rats: Dose-dependent lipogenic effects without concomitant weight gain
Fernø, J., Ersland, K. M., Duus, I. H., González‐García, I., Fossan, K. O., Berge, R. K., Steen, V. M., & Skrede, S. (2015) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2015.03.002 · Cited by 43
Differential effects of antipsychotic medications on polyunsaturated fatty acid biosynthesis in rats: Relationship with liver delta6-desaturase expression
McNamara, R. K., Jandacek, R. J., Rider, T., Tso, P., Cole-Strauss, A., & Lipton, J. W. (2011) · Schizophrenia Research · doi:10.1016/j.schres.2011.03.006 · Cited by 40
Effects of Switching From Olanzapine, Quetiapine, and Risperidone to Aripiprazole on 10-Year Coronary Heart Disease Risk and Metabolic Syndrome Status: Results From a Randomized Controlled Trial
Stroup, T. S., Byerly, M. J., Nasrallah, H. A., Ray, N., Khan, A. Y., Lamberti, J. S., Glick, I. D., Steinbook, R. M., McEvoy, J. P., & Hamer, R. M. (2013) · Schizophrenia Research · doi:10.1016/j.schres.2013.01.013 · Cited by 39
Self-citation
Obesity, cardiovascular disease and type 2 diabetes in people with a mental illness: a need for primary health care
Stanley, S. H., & Laugharne, J. D. E. (2011) · Australian Journal of Primary Health · doi:10.1071/py11045 · Cited by 38
Drugs That Affect Body Weight, Body Fat Distribution, and Metabolism
Verhaegen, A. A., & Gaal, L. F. V. (2019) · Europe PMC (PubMed Central) · Cited by 38
Metabolic parameters in the short- and long-term treatment of schizophrenia with sertindole or risperidone
Binder, M. D., Mittoux, A., He, Y., & Peuskens, J. (2010) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-010-0142-x · Cited by 38
Management of serious cardiac adverse effects of antipsychotic medications
Stoner, S. C. (2017) · Mental Health Clinician · doi:10.9740/mhc.2017.11.246 · Cited by 37
Protection from olanzapine-induced metabolic toxicity in mice by acetaminophen and tetrahydroindenoindole
Shertzer, H. G., Kendig, E. L., Nasrallah, H. A., Johansson, E., & Genter, M. B. (2010) · International Journal of Obesity · doi:10.1038/ijo.2009.291 · Cited by 39
Self-citation
Antipsychotics and Metabolics in the Post-CATIE Era
Meyer, J. M. (2010) · Current topics in behavioral neurosciences · doi:10.1007/7854_2010_45 · Cited by 36
Self-citation
Persistence of racial disparities in prescription of first-generation antipsychotics in the USA
Cook, T. B., Reeves, G. M., Teufel, J. A., & Postolache, T. T. (2015) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.3819 · Cited by 37
Directions for Future Patient-Centered and Comparative Effectiveness Research for People With Serious Mental Illness
The University of North Carolina at Chapel Hill University Libraries (2014) · Schizophrenia Bulletin · doi:10.1093/schbul/sbt170 · Cited by 48
Can Exercise Increase Fitness and Reduce Weight in Patients with Schizophrenia and Depression?
Krogh, J., Speyer, H., Nørgaard, H. C. B., Moltke, A., & Nordentoft, M. (2014) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2014.00089 · Cited by 37
Increased Framingham 10-year CVD risk in Chinese patients with schizophrenia
Tay, Y. H., Nurjono, M., & Lee, J. (2013) · Schizophrenia Research · doi:10.1016/j.schres.2013.03.023 · Cited by 35
STRIDE: a randomized trial of a lifestyle intervention to promote weight loss among individuals taking antipsychotic medications
Yarborough, B. J. H., Leo, M. C., Stumbo, S. P., Perrin, N., & Green, C. A. (2013) · BMC Psychiatry · doi:10.1186/1471-244x-13-238 · Cited by 35
Patients taking medications for bipolar disorder are more prone to metabolic syndrome than Korea's general population
Lee, N. Y., Kim, S. H., Cho, B., Lee, Y. J., Chang, J. S., Kang, U. G., Kim, Y. S., & Ahn, Y. M. (2010) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2010.06.029 · Cited by 33
Recent advances in understanding and mitigating adipogenic and metabolic effects of antipsychotic drugs
Gohlke, J. M. (2012) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2012.00062 · Cited by 32
Improving the physical health of long-term psychiatric inpatients
Hjorth, P., Davidsen, A., Kilian, R., Eriksen, S. P., Jensen, S. O. W., Sørensen, H. Ø., & Munk-Jørgensen, P. (2014) · Australian and New Zealand journal of psychiatry (Print) · doi:10.1177/0004867414533011 · Cited by 31
Comparison of metabolic and prolactin variables from a six-month randomised trial of olanzapine and quetiapine in schizophrenia
Bushe, C., Sniadecki, J. L., Bradley, A., & Hoffmann, V. P. (2009) · Journal of Psychopharmacology · doi:10.1177/0269881108101783 · Cited by 31
Long-term safety and tolerability of aripiprazole lauroxil in patients with schizophrenia
Nasrallah, H. A., Aquila, R., Du, Y., Stanford, A. D., Claxton, A., & Weiden, P. J. (2018) · CNS Spectrums · doi:10.1017/s1092852918001104 · Cited by 29
Self-citation
Exploring mechanisms of increased cardiovascular disease risk with antipsychotic medications: Risperidone alters the cardiac proteomic signature in mice
Beauchemin, M., Geguchadze, R., Guntur, A. R., Nevola, K. T., Le, P. T., Barlow, D. J., Rue, M., Vary, C., Lary, C. W., Motyl, K. J., et al. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.104589 · Cited by 31
Weight maintenance following the STRIDE lifestyle intervention for individuals taking antipsychotic medications
Green, C. A., Yarborough, B. J. H., Leo, M. C., Stumbo, S. P., Perrin, N., Nichols, G. A., & Stevens, V. J. (2015) · Obesity · doi:10.1002/oby.21205 · Cited by 30
Regional Differences in Five-Year Mortality After a First Episode of Schizophrenia in Finland
Kiviniemi, M., Suvisaari, J., Pirkola, S. P., Häkkinen, U., Isohanni, M. K., & Hakko, H. H. (2010) · Psychiatric Services · doi:10.1176/ps.2010.61.3.272 · Cited by 32
TAILOR – tapered discontinuation versus maintenance therapy of antipsychotic medication in patients with newly diagnosed schizophrenia or persistent delusional disorder in remission of psychotic symptoms: study protocol for a randomized clinical trial
Stürup, A. E., Jensen, H., Dolmer, S., Birk, M., Albert, N., Nielsen, M., Hjorthøj, C. R., Eplov, L. F., Ebdrup, B. H., Mors, O. N., et al. (2017) · Trials · doi:10.1186/s13063-017-2172-4 · Cited by 31
Predictors of metabolic monitoring among schizophrenia patients with a new episode of second-generation antipsychotic use in the Veterans Health Administration
Shi, L., Ascher‐Svanum, H., Chiang, Y., Zhao, Y., Fonseca, V. A., & Winstead, D. K. (2009) · BMC Psychiatry · doi:10.1186/1471-244x-9-80 · Cited by 28
Pretreatment levels of the fatty acid handling proteins H-FABP and CD36 predict response to olanzapine in recent-onset schizophrenia patients
Tomasik, J., Schwarz, E., Lago, S. G., Rothermundt, M., Leweke, F. M., van Beveren, N. J. M., Guest, P. C., Rahmoune, H., Steiner, J. H., & Bahn, S. (2015) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2015.10.019 · Cited by 27
Decreased cardiovascular death in schizophrenia patients treated with antipsychotics: A Korean national cohort study
Oh, J., Nam, H., Park, S. M., Chae, J., & Kim, T. (2021) · Schizophrenia Research · doi:10.1016/j.schres.2021.01.006 · Cited by 28
Antipsychotic medication, mortality and neurodegeneration: The need for more selective use and lower doses
Weinmann, S., & Aderhold, V. (2009) · Psychosis · doi:10.1080/17522430903501999 · Cited by 28
PAOPA, a potent dopamine D2 receptor allosteric modulator, prevents and reverses behavioral and biochemical abnormalities in an amphetamine-sensitized preclinical animal model of schizophrenia.
Beyaert, M. G. R., Daya, R. P., Dyck, B. A., Johnson, R. L., & Mishra, R. (2013) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2012.04.010 · Cited by 28
Cardiovascular disease and diabetes in people with severe mental illness
Binder, M. D., Dekker, J. M., Wood, D. A., Kahl, K. G., & Möller, H. (2009) · Revista de Psiquiatría y Salud Mental (English Edition) · doi:10.1016/s2173-5050(09)70031-7 · Cited by 27
A comparison of cardiovascular risk factors for ten antipsychotic drugs in clinical practice
Bodén, R., Edman, Reutfors, J., Östenson, C., & Ösby (2013) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s40554 · Cited by 27
Roles in and barriers to metabolic screening for people taking antipsychotic medications: A survey of psychiatrists
Parameswaran, S., Chang, C. H., Swenson, A., Shumway, M., Olfson, M., & Mangurian, C. V. (2012) · Schizophrenia Research · doi:10.1016/j.schres.2012.08.031 · Cited by 26
Multiple Aspects of Inappropriate Action of Renin–Angiotensin, Vasopressin, and Oxytocin Systems in Neuropsychiatric and Neurodegenerative Diseases
Szczepanska‐Sadowska, E. K., Wsół, A., Cudnoch‐Jędrzejewska, A., Czarzasta, K., & Żera, T. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11040908 · Cited by 26
Standard cardiovascular disease risk algorithms underestimate the risk of cardiovascular disease in schizophrenia: Evidence from a national primary care database
McLean, G., Martin, J. L., Martin, D. J., Guthrie, B., Mercer, S. W., & Smıth, D. J. (2014) · Schizophrenia Research · doi:10.1016/j.schres.2014.07.022 · Cited by 25
Use of Antipsychotics and Risk of Cerebrovascular Events in Schizophrenic Patients
Hsieh, P.-H., Hsiao, F., Gau, S. S., & Gau, C. (2013) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3182900dfe · Cited by 26
Exercise Program Adherence Using a 5-Kilometer (5K) Event as an Achievable Goal in People With Schizophrenia
Warren, K. R., Ball, M. P., Feldman, S. M., Liu, F., McMahon, R. P., & Kelly, D. L. (2010) · Biological Research For Nursing · doi:10.1177/1099800410393272 · Cited by 23
Enfermedad cardiovascular y diabetes en personas con enfermedad mental grave
Hert, M. D., Dekker, J. M., Wood, D. A., Kahl, K. G., & Möller, H. (2009) · Revista de Psiquiatría y Salud Mental · doi:10.1016/s1888-9891(09)70714-1 · Cited by 23
The prevalence of cardiometabolic risk factors and the ten-year risk of fatal cardiovascular events in patients with schizophrenia and related psychotic disorders.
Protopopová, D., Masopust, J., Malý, R., Vališ, M., & Bažant, J. (2012) · PubMed · Cited by 23
Changes in metabolic parameters in patients with severe mental illness over a 10-year period: A retrospective cohort study
Heald, A., Martin, J. L., Payton, T., Khalid, L., Anderson, S., Narayanan, R., de Hert, M., Yung, A., & Livingston, M. (2017) · Australian and New Zealand journal of psychiatry (Print) · doi:10.1177/0004867415625817 · Cited by 26

Authors: Daumit, G. L., Goff, D. C., Meyer, J. M., Davis, V. G., Nasrallah, H. A., McEvoy, J. P., Rosenheck, R., Davis, S. M., Hsiao, J. K., Stroup, T. S., & Lieberman, J. A.
Affiliations: Johns Hopkins University (US)
Harvard University (US)
University of California San Diego (US)
Bank of America (US)
University of Cincinnati (US)
Duke University (US)
Yale University (US)
National Institutes of Health (US)
University of North Carolina at Chapel Hill (US)
Columbia University (US)
Corresponding author: Daumit, Gail L.
ORCID: Daumit, Gail L.
Goff, Donald C.
Meyer, Jonathan M.
Nasrallah, Henry A.
McEvoy, Joseph P.
Rosenheck, Robert
Hsiao, John K.
Stroup, T. Scott
Lieberman, Jeffrey A.
Venue: Schizophrenia Research
Publisher: Elsevier BV
Published: 2008-10
Volume: 105
Issue: 1-3
Pages: 175-187
ISSN: 0920-9964 (ISSN-L)
DOI: 10.1016/j.schres.2008.07.006
PMC: PMC2614656
OpenAlex: W2107325590
Cited by: 223
References: 44
Citations by year: 2026: 2 · 2025: 3 · 2024: 8 · 2023: 2 · 2022: 6 · 2021: 9 · 2020: 6 · 2019: 11 · 2018: 11 · 2017: 13 · 2016: 10 · 2015: 20 · 2014: 16 · 2013: 24 · 2012: 20
FWCI: 14.52
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
Locations: Schizophrenia Research (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Funders: National Institute of Mental Health (1MH900001)
Topics: Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Health and Mental Health
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
Keywords: antipsychotic drugs, coronary heart disease risk
MeSH terms: Adult, Coronary Disease, Female, Follow-Up Studies, Humans, Hypertension, Longitudinal Studies, Male, Obesity, Patient Dropouts, Risk Factors, Schizophrenia, Schizophrenic Psychology, Smoking, Antipsychotic Agents, Weight Gain, Comorbidity, Treatment Outcome, Outcome Assessment, Health Care, Risk Assessment

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Antipsychotic effects on estimated 10-year coronary heart disease risk in the CATIE schizophrenia study

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks